A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

Document Type

Article

Publication Title

Oncotarget

Abstract

Ovarian cancer is common gynaecological malignancy and a leading cause of death among women. Despite the advances in treatment strategies, majority of patients present with recurrence after first- or second-line treatment. Targeted therapy that has proven to be effective in other advanced or metastatic solid tumors have also demonstrated its efficacy in ovarian cancer. Recent studies have shown that the androgen receptor (AR) signalling is involved in pathogenicity and progression of cancer. Current observations suggest AR could be a potential target in managing the disease. In this case report we present a patient with high grade serous ovarian cancer (HGSOC) with multiple relapses with excellent disease control on AR inhibition with bicalutamide.

First Page

4358

Last Page

4363

DOI

10.18632/ONCOTARGET.27809

Publication Date

11-1-2020

This document is currently not available here.

Share

COinS